Sarepta (SRPT) calls active after FDA approves eteplirsen

Sarepta (SRPT) Wins Key PTO Decision on Composition of Matter Patents - Oppenheimer

Oppenheimer analyst Michelle Gilson notes US Patent and Trademark Office ruled in favor of Sarepta (NASDAQ: SRPT) for Patents 7,960,541 and 7,807,816 in its patent interference proceeding (interference number 106,008).

Gilson notes these cover composition of matter for eteplirsen, giving the Sarepta freedom to operate... More

Sarepta Therapeutic (SRPT) PT Raised to $66 at Wedbush

Wedbush analyst Heather Behanna reiterated an Outperform rating and boosted her price target on Sarepta Therapeutic (NASDAQ: SRPT) to $66.00 (from $36.00) after the FDA approved eteplirsen.

Behanna commented, "In line with our expectations after FDA asked for new data, eteplirsen has received accelerated... More

Sarepta Therapeutic (SRPT) PT Raised to $81 at Needham & Company

Needham & Company analyst Chad Messer reiterated a Buy rating and raised his price target on Sarepta Therapeutic (NASDAQ: SRPT) to $81.00 (from $47.00) following eteplirsen approval.

Messer commented, "The FDA has granted conditional approval to eteplirsen (Exondys 51) stating that data on dystrophin production was "reasonably... More

Leerink Partners Upgrades Sarepta Therapeutic (SRPT) to Market Perform

Leerink Partners upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Underperform to Market Perform with a price target of $50.00 (from $5.00).

Analyst Joseph Schwartz commented, "Sarepta's eteplirsen (Exondys 51, Duchenne Muscular Dystrophy) surprisingly received FDA's accelerated approval (AA), in stark contrast to the FDA's negative commentary... More

Sarepta (SRPT) PT Raised to $76 at Oppenheimer Amid Eteplirsen Approval

Oppenheimer analyst Michelle Gilson reiterated an Outperform rating and raised her price target on Sarepta Therapeutic (NASDAQ: SRPT) to $76.00 (from $60.00) after the FDA announced the approval of eteplirsen (EXONDYS 51) for the treatment of all boys with DMD amenable to Exon 51 skipping.

Gilson... More

Sarepta Therapeutics (SRPT) Pushes to Highs Following FDA Approval; +90%

Sarepta Therapeutics (NASDAQ: SRPT) trading at the highs of the session following FDA approval. Shares are up 90.7%

Sarepta Therapeutic (SRPT) Label More Inclusive Than Anticipated - Oppenheimer

Oppenheimer analyst Michelle Gilson reiterated an Outperform rating and $60 price target on Sarepta Therapeutic (NASDAQ: SRPT) after the FDA announced the approval of eteplirsen (EXONDYS51) for the treatment of DMD amenable to Exon 51 skipping.

In conjunction with eteplirsen's accelerated approval, Sarepta will... More